RxDoctor Payments Data

Jeffrey Jones, MD

Family Medicine · West Brookfield, MANPI 1437144011

Payments from drug & device makers

$803in general payments, 2019–2025

Across 45 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$292
  • Vanda Pharmaceuticals Inc.$173
  • Indivior Inc.$125
  • Abbott$71
  • Lundbeck LLC$44
  • Inogen, Inc.$33
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$63078%
  • Education$17322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie14$292
Vanda Pharmaceuticals Inc.16$173
Indivior Inc.4$125
Abbott4$71
Lundbeck LLC2$44
Inogen, Inc.1$33
Novo Nordisk1$25
GSK2$24
Phathom Pharmaceuticals, Inc.1$16

How this compares

$803 in reported general payments places this provider in the 80th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$168,001
Medicare patients
361
Services billed
2,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole37$68,651
EliquisApixaban98$62,779
TrulicityDulaglutide42$43,374
OxycontinOxycodone Hcl38$40,557
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl199$32,068
MounjaroTirzepatide26$28,248
JardianceEmpagliflozin39$23,595
Breo ElliptaFluticasone/Vilanterol52$22,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$21,158
JanuviaSitagliptin Phosphate17$20,272
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$16,263
OzempicSemaglutide14$13,061
FarxigaDapagliflozin Propanediol14$10,064
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,488
Oxycodone Hcl307$8,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$24$64,853119 claims
Novo NordiskOzempic$25$13,06114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in West Brookfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →